Cardiovascular manifestations of inflammatory bowel diseases and the underlying pathogenic mechanisms
- 1 August 2023
- journal article
- review article
- Published by American Physiological Society in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
- Vol. 325 (2) , R193-R211
Abstract
Inflammatory bowel disease (IBD), consisting of ulcerative colitis and Crohn’s disease, mainly affects the gastrointestinal tract but is also known to have extraintestinal manifestations because of long-standing systemic inflammation. Several national cohort studies have found that IBD is an independent risk factor for the development of cardiovascular disorders. However, the molecular mechanisms by which IBD impairs the cardiovascular system are not fully understood. Although the gut-heart axis is attracting more attention in recent years, our knowledge of the organ-to-organ communication between the gut and the heart remains limited. In patients with IBD, upregulated inflammatory factors, altered microRNAs and lipid profiles, as well as dysbiotic gut microbiota, may induce adverse cardiac remodeling. In addition, patients with IBD have a three- to four times higher risk of developing thrombosis than people without IBD, and it is believed that the increased risk of thrombosis is largely due to increased procoagulant factors, platelet count/activity, and fibrinogen concentration, in addition to decreased anticoagulant factors. The predisposing factors for atherosclerosis are present in IBD and the possible mechanisms may involve oxidative stress system, overexpression of matrix metalloproteinases, and changes in vascular smooth muscle phenotype. This review focuses mainly on 1) the prevalence of cardiovascular diseases associated with IBD, 2) the potential pathogenic mechanisms of cardiovascular diseases in patients with IBD, and 3) adverse effects of IBD drugs on the cardiovascular system. Also, we introduce here a new paradigm for the gut-heart axis that includes exosomal microRNA and the gut microbiota as a cause for cardiac remodeling and fibrosis.Keywords
Funding Information
- HHS | NIH | National Heart, Lung, and Blood Institute (R01 HL152683)
This publication has 234 references indexed in Scilit:
- p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activationCellular Signalling, 2013
- No Increased Risk of Myocardial Infarction Among Patients With Ulcerative Colitis or Crohn's DiseaseClinical Gastroenterology and Hepatology, 2011
- Defective Leukocyte GM-CSF Receptor (CD116) Expression and Function in Inflammatory Bowel DiseaseGastroenterology, 2011
- Reproducible Community Dynamics of the Gastrointestinal Microbiota following Antibiotic PerturbationInfection and Immunity, 2009
- The role of IL-1 in the pathogenesis of heart diseaseArchivum Immunologiae et Therapiae Experimentalis, 2009
- Use of atorvastatin as an anti‐inflammatory treatment in Crohn's diseaseBritish Journal of Pharmacology, 2008
- Role of gp130‐mediated signalling pathways in the heart and its impact on potential therapeutic aspectsBritish Journal of Pharmacology, 2008
- TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathwaysJournal of Clinical Investigation, 2007
- IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling systemJournal of Clinical Investigation, 2007
- The Clustering of Other Chronic Inflammatory Diseases in Inflammatory Bowel Disease: A Population-Based StudyGastroenterology, 2005